alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Federal Register Volume 80, Number 195 (Thursday, October 8, 2015)]
[Notices]
[Page 60950]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-25402]

[[Page 60950]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Thirty-Sixth Meeting: Special Committee (224) Airport Security 
Access Control Systems

AGENCY: Federal Aviation Administration (FAA), U.S. Department of 
Transportation (DOT).

ACTION: Notice of Thirty-Sixth Special Committee 224 Meeting.

-----------------------------------------------------------------------

SUMMARY: The FAA is issuing this notice to advise the public of the 
thirty-sixth Special Committee 224 meeting.

DATES: The meeting will be held October 29th from 10:00 a.m.-3:00 p.m.

ADDRESSES: The meeting will be held at RTCA, Inc., 1150 18th Street 
NW., Suite 450, Washington, DC 20036, Tel: (202) 330-0680.

FOR FURTHER INFORMATION CONTACT: The RTCA Secretariat, 1150 18th Street 
NW., Suite 910, Washington, DC 20036, or by telephone at (202) 833-
9339, fax at (202) 833-9434, or Web site at http://www.rtca.org or 
Karan Hofmann, Program Director, RTCA, Inc., khofmann@rtca.org, (202) 
330-0680.

SUPPLEMENTARY INFORMATION: Pursuant to section 10(a) (2) of the Federal 
Advisory Committee Act (Pub. L. 92-463, 5 U.S.C., App.), notice is 
hereby given for a meeting of Special Committee 224. The agenda will 
include the following:

Thursday, October 29, 2015

1. Welcome/Introductions/Administrative Remarks
2. Review/Approve Previous Meeting Summary
3. Report from the TSA
4. Report on Safe Skies on Document Distribution
5. Review of FRAC comments/worksheet and committee resolution of 
comments
6. Approve release of DO-230 F to go to PMC
7. Review of Other DO-230G Sections
8. Action Items for Next Meeting
9. Time and Place of Next Meeting
10. Any Other Business
11. Adjourn

    Attendance is open to the interested public but limited to space 
availability. With the approval of the chairman, members of the public 
may present oral statements at the meeting. Persons wishing to present 
statements or obtain information should contact the person listed in 
the FOR FURTHER INFORMATION CONTACT section. Members of the public may 
present a written statement to the committee at any time.

    Issued in Washington, DC, on September 30, 2015.
Latasha Robinson,
Management & Program Analyst, Next Generation, Enterprise Support 
Services Division, Federal Aviation Administration.
[FR Doc. 2015-25402 Filed 10-7-15; 8:45 am]
 BILLING CODE 4910-13-P
```
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.5560 Electrical salivary stimulatory system. ( a ) *Identification.* An electrical salivary stimulatory system is a prescription intraoral device that is intended to electrically stimulate a relative increase in saliva production.
( b ) *Classification* —Class II (special controls). The special controls for this device are: ( 1 ) The design characteristics of the device must ensure that the device design, material composition, and electrical output characteristics are consistent with the intended use;
( 2 ) Any element of the device that contacts the patient must be demonstrated to be biocompatible;
( 3 ) Appropriate analysis and/or testing must validate electromagnetic compatibility and electrical safety, including the safety of any battery used in the device;
( 4 ) Software validation, verification, and hazard testing must be performed; and
( 5 ) Documented clinical experience must demonstrate safe and effective use for stimulating saliva production by addressing the risks of damage to intraoral tissue and of ineffective treatment and must capture any adverse events observed during clinical use.
[80 FR 72586, Nov. 22, 2015]
[if !vml]>[endif]>
[if !vml]>[endif]>
Youhave reached the Federal Depository Library Program Electronic Collection(FDLP/EC) Archive. This archive assures ongoing access to publications in theFDLP/EC. Access to publications in the archive is available through GPO's suiteof cataloging and locator services, including the Catalog of U.S. GovernmentPublications (CGP).
**Title:****Standard technical specifications,Westinghouse plants.
 
Vol. 1| Vol. 2
 
SuDoc Number:Y 3.N 88:10/1431/REV.4/V.1-2
Item Number:1051-H-48 (online)
CGP System Number:001017418
 
 
 
** 
**Permanent Public Access
** 
Title 44 of  the United States Code (44 U.S.C. Section 1911) stipulates that public access  to official Government information products disseminated through the Federal  Depository Library Program (FDLP) must be maintained permanently in regional  depository libraries and by depository libraries not served by a regional  library. Since online products are not physically distributed to depository  libraries for retention, GPO has assumed responsibility for the provision of  permanent access to Government information products residing on FDsys  servers.
GPO's  permanent public access commitment is also met by bringing  agency-disseminated Internet resources under the purview of GPO and  incorporating them into a digital archive. GPO captures copies of agency  electronic information products, and creates PURLs so that users will be  automatically redirected to the archived products if the information is no  longer accessible on the agency Web site. Please refer to the report Managing  the FDLP Electronic Collection: A Policy and Planning Document for more  information.
 
August 29, 2017********
Exhibit 35.5



|     |                        |                               |  | 
|---- | ---------------------- | ----------------------------- |  | 
|LOGO |                        | Commercial Mortgage Servicing |  | 
|     | D1050-084, 8th Floor   |                               | 
|     | 401 South Tryon Street |                               | 
|     | Charlotte, NC 28202    |                               | 
|     | 1-800-326-1334         |                               | 

ANNUAL STATEMENT OF COMPLIANCE

Reference is hereby made to that certain Pooling and Servicing Agreement dated as of August 1, 2015, by and among DEUTSCHE
MORTGAGE & ASSET RECEIVING CORPORATION, as Depositor, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Master Servicer, LNR PARTNERS, LLC, as Special Servicer, WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee, and WELLS FARGO BANK, NATIONAL
ASSOCIATION, as Certificate Administrator, Paying Agent and Custodian, and PARK BRIDGE LENDER SERVICES LLC, as Operating Advisor with respect to Commercial Mortgage Pass-Through Certificates, COMM 2015-CCRE24 (the Agreement). Capitalized
terms used herein not otherwise defined shall have the meanings assigned in the Agreement.

Pursuant to Section 10.11 of this
Agreement, I, Daniel Bober, Executive Vice President of Commercial Mortgage Services do hereby certify that:



| | 1. | A review of the activities of the Master Servicer during the period from January 1, 2016 through December 31, 2016 (the Reporting Period), and of its performance per the Agreement during such
period has been made under my supervision, and
| | -- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 2. | To the best of my knowledge, based on such review, the Master Servicer has fulfilled all of its obligations under the Agreement in all material respects throughout the Reporting Period.
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IN WITNESS WHEREOF, the undersigned has executed this Certificate as of the 28th day of
February 2017.



|                        
|------------------------
|LOGO                    
|                        
|Daniel Bober            
|Executive Vice President
|Wells Fargo Bank        



|                       |  |     
|---------------------- |  | ----
|Wells Fargo Bank, N.A. |  | LOGO
EXHIBIT 32.2

                  CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
                       ARMANINO FOODS OF DISTINCTION, INC.
                       PURSUANT TO 18 U.S.C. SECTION 1350


     I hereby certify that, to the best of my knowledge, the Quarterly Report
on Form 10-QSB of Armanino Foods of Distinction, Inc. for the period ending
March 31, 2005:

     (1) complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and

     (2) the information contained in the Report fairly presents, in all
material aspects, the financial condition and results of operations of
Armanino Foods of Distinction, Inc.





/s/ Edmond J. Pera
Edmond J. Pera
Chief Operating Officer
(Principal Financial Officer)
May 12, 2005


A signed original of this written statement required by Section 906 of the
Sarbanes-Oxley Act of 2002 has been provided to Armanino Foods of Distinction,
Inc. and will be retained by Armanino Foods of Distinction, Inc. and furnished
to the Securities and Exchange Commission upon request.
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4590 Focused ultrasound stimulator system for aesthetic use. ( a ) *Identification.* A Focused Ultrasound Stimulator System for Aesthetic Use is a device using focused ultrasound to produce localized, mechanical motion within tissues and cells for the purpose of producing either localized heating for tissue coagulation or for mechanical cellular membrane disruption intended for noninvasive aesthetic use.
( b ) *Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Focused Ultrasound Stimulator System for Aesthetic Use.” See § 878.1(e) for the availability of this guidance document.
[76 FR 43121, July 20, 2011]
PUBLIC LAW 115–297—DEC. 6, 2018 132 STAT. 4381 

LEGISLATIVE HISTORY—H.R. 6116: 

CONGRESSIONAL RECORD, Vol. 164 (2018): 

Sept. 13, considered and passed House. 

Nov. 15, considered and passed Senate. 

Æ 

Public Law 115–297 

115th Congress 

An Act 

To designate the facility of the United States Postal Service located at 362 North 

Ross Street in Beaverton, Michigan, as the ‘‘Colonel Alfred Asch Post Office’’. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. COLONEL ALFRED ASCH POST OFFICE. 

(a) DESIGNATION.—The facility of the United States Postal 

Service located at 362 North Ross Street in Beaverton, Michigan, 

shall be known and designated as the ‘‘Colonel Alfred Asch Post 

Office’’. 

(b) REFERENCES.—Any reference in a law, map, regulation, 

document, paper, or other record of the United States to the facility 

referred to in subsection (a) shall be deemed to be a reference 

to the ‘‘Colonel Alfred Asch Post Office’’. 

Approved December 6, 2018. 

Dec. 6, 2018 

[H.R. 6116] 


ralbany on LAP520R082 with PUB LAWS PDF
EXHIBIT 10.7


                                 PROMISSORY NOTE

$20,000.00                        Dallas, Texas                  October 1, 1998

         FOR VALUE  RECEIVED,  Preferred  Voice,  Inc.,  a Delaware  corporation
promises to pay to the order of Bisbro  Investments Co., Ltd., at P.O. Box 3444,
Road Town,  Tortola,  British  Virgin  Islands,  or at such other address as the
holder  hereof may  designate,  the  principal  sum of Twenty  Thousand  Dollars
($20,000.00),  together with interest on the unpaid  principal  balance from the
date hereof until this note is paid in full at a rate of 10% per annum.

         Principal and interest  shall be payable in one  installment on October
1, 1999.

         All payments  received shall be applied first to the payment of accrued
interest and then to the payment of principal.

         Maker shall have the right to prepay any and all amounts due  hereunder
without penalty for the privilege of doing so.

         No payment shall be considered in default  unless it is not paid within
ten (10) days after delivery of written notice of nonpayment.

         Holder will have the right at any time to convert this note into shares
of common stock,  $.001 par value per share, of Maker, at the conversion rate of
one share of common  stock for each $.50 of  principal  and  interest due on the
note on the date of conversion.

         In the event  default is made in the  payment of this Note,  the unpaid
balance on this Note shall at once become due and payable,  without  notice,  at
the option of the Holder. Failure to exercise this option shall not constitute a
waiver of the right to declare the entire  principal  due and payable at once at
any subsequent time.

         If, after default,  this Note is placed in the hands of an attorney for
collection,  or if collected  through judicial  proceeding,  Maker shall pay, in
addition to the sums  referred to above,  a reasonable  sum as a  collection  or
attorneys'  fee and all other  costs  incurred  by Holder in  collection  of the
unpaid amounts due hereunder.

         Each maker, surety,  guarantor,  endorser or other party liable for the
payment of this Note, in whole or in part,  hereby expressly waives  presentment
and demand for payment,  notice of intention to accelerate  maturity,  notice of
acceleration of maturity, protest and notice of protest and nonpayment, bringing
of suit and  diligence  in taking any action to collect sums owing  hereon,  and
agree that this Note,  and any payment  hereunder,  may be extended from time to
time without in any way affecting such liability.

MAKER:

Preferred Voice, Inc.


----------------------
G. Ray Miller
Its: President
Exhibit








Exhibit 10.2
 
RETROPHIN, INC.
Amendment to Employment Agreement
This Amendment (the “Amendment”) is entered into as of April 11, 2017 and modifies the Employment Agreement (the “Agreement”) dated March 3, 2015 by and between Retrophin, Inc. (the “Company”) and Laura Clague (“Executive”).  All capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Agreement.
The parties hereto, intending to be legally bound, agree to amend the Agreement as follows:
		
	1.
	Article 6, Section 6.8(a) of the Agreement shall be amended and restated in its entirety as follows:


“Severance Benefits.  If (i) within three (3) months prior to, or on or within twelve (12) months after, the consummation of a Change in Control (as defined in Section 6.8(b) herein), (1) the Company terminates Executive’s employment and this Agreement without Cause pursuant to Section 6.5 herein or (2) Executive resigns his or her employment and terminates this Agreement as a result of a Constructive Termination pursuant to Section 6.6 herein, and (ii) in either event (1) or (2), Executive signs the Release on or within the time period set forth therein, but in no event later than forty-five (45) days after the termination date and allows such Release to become effective, then Executive shall receive the following severance benefits in lieu of any severance benefits set forth in Section 6.5(b) or Section 6.6(b) herein:” 
		
	2.
	The Agreement and this Amendment represent the complete and entire understanding between the parties regarding the subject matter hereof and supersede all prior negotiations, representations or agreements, either written or oral, regarding this subject matter.  No provisions of this Amendment may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing signed by Executive and such officer as may be specifically designated by the Board of Directors of the Company. 


		
	3.
	The validity, interpretation, construction and performance of this Amendment and the rights of the parties thereunder shall be interpreted and enforced under California law without reference to principles of conflicts of laws.  


		
	4.
	This Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.


		
	5.
	Except for the matters set forth in this Amendment, all other terms of the Agreement shall remain unchanged and in full force and effect.


In Witness Whereof, the parties hereto have duly executed this Amendment as of the date set forth above.


	
				
	 
	 
	RETROPHIN, INC.

	 
	 
	 
	 

	 
	 
	By:
	/s/ Stephen Aselage

	 
	 
	Name:
	Stephen Aselage

	 
	 
	Title:
	Chief Executive Officer

	 
	 
	 
	 

	Accepted and agreed:
	 
	 
	 

	 
	 
	 
	 

	/s/ Laura Clague
	 
	 
	 

	Laura Clague
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4100 Organ bag. ( a ) *Identification.* An organ bag is a device that is a flexible plastic bag intended to be used as a temporary receptacle for an organ during surgical procedures to prevent moisture loss.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 878.9.
[53 FR 23872, June 24, 1988, as amended at 59 FR 63010, Dec. 7, 1994; 65 FR 2318, Jan. 14, 2000]
**Exhibit 23**

**Consent of Independent Registered Public Accounting Firm**

The Board of Directors 

ViroPharma Incorporated: 

We consent to the incorporation byreference in the registration statements on Form S-8 (No. 333-136447, No. 333-34129, No. 333-38248, No. 333-60951, No. 333-38256, No. 333-109600 and No. 333-127188) and registration statements on Form S-3 (No.333-37960, No. 333-64482, No. 333-99533, No. 333-122315 and No. 333-123994) of ViroPharma Incorporated of our reports dated February 27, 2006, with respect to the consolidated balance sheets of ViroPharma Incorporated andsubsidiaries as of December 31, 2006 and 2005, and the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity (deficit) and cash flows for each of the years in the three-year period endedDecember 31, 2006, management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2006 and the effectiveness of internal control over financial reporting as of December 31, 2006,which reports appear in the December 31, 2006 Annual Report on Form 10-K of ViroPharma Incorporated. 

Our report on the consolidatedfinancial statements refers to the Company’s adoption of the provisions of Statement of Financial Accounting Standards No. 123R, “Share-Based Payment,” effective January 1, 2006. 

/s/ KPMG LLP 

McLean, VA 

February 27, 2007
§ 876.5860 High permeability hemodialysis system. ( a ) *Identification.* A high permeability hemodialysis system is a device intended for use as an artificial kidney system for the treatment of patients with renal failure, fluid overload, or toxemic conditions by performing such therapies as hemodialysis, hemofiltration, hemoconcentration, and hemodiafiltration. Using a hemodialyzer with a semipermeable membrane that is more permeable to water than the semipermeable membrane of the conventional hemodialysis system (§ 876.5820), the high permeability hemodialysis system removes toxins or excess fluid from the patient's blood using the principles of convection (via a high ultrafiltration rate) and/or diffusion (via a concentration gradient in dialysate). During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the blood to the dialysate compartment. The hemodialysis delivery machine controls and monitors the parameters related to this processing, including the rate at which blood and dialysate are pumped through the system, and the rate at which fluid is removed from the patient. The high permeability hemodialysis system consists of the following devices: ( 1 ) The hemodialyzer consists of a semipermeable membrane with an in vitro ultrafiltration coefficient (Kuf) greater than 8 milliliters per hour per conventional millimeter of mercury, as measured with bovine or expired human blood, and is used with either an automated ultrafiltration controller or anther method of ultrafiltration control to prevent fluid imbalance.
( 2 ) The hemodialysis delivery machine is similar to the extracorporeal blood system and dialysate delivery system of the hemodialysis system and accessories (§ 876.5820), with the addition of an ultrafiltration controller and mechanisms that monitor and/or control such parameters as fluid balance, dialysate composition, and patient treatment parameters (e.g., blood pressure, hematocrit, urea, etc.).
( 3 ) The high permeability hemodialysis system accessories include, but are not limited to, tubing lines and various treatment related monitors (e.g., dialysate pH, blood pressure, hematocrit, and blood recirculation monitors).
( b ) *Classification.* Class II. The special controls for this device are FDA's: ( 1 ) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Device—Part I: Evaluation and Testing,’ ”
( 2 ) “Guidance for the Content of 510(k)s for Conventional and High Permeability Hemodialyzers,”
( 3 ) “Guidance for Industry and CDRH Reviewers on the Content of Premarket Notifications for Hemodialysis Delivery Systems,”
( 4 ) “Guidance for the Content of Premarket Notifications for Water Purification Components and Systems for Hemodialysis,” and
( 5 ) “Guidance for Hemodialyzer Reuse Labeling.”
[65 FR 17145, Mar. 31, 2000]
<Page>

                                                                      EXHIBIT 32

                  CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
                           PURSUANT TO 18 U.S.C. 1350
                (SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

    I, Albo J. Antenucci, Jr., President and Chief Executive Officer (Principal
Executive Officer) of American Property Investors, Inc., the General Partner of
American Real Estate Partners, L.P. (the 'Registrant'), certify that to the best
of my knowledge, based upon a review of the American Real Estate Partners, L.P.
Quarterly Report on Form 10-Q for the period ended June 30, 2003 of the
Registrant (the 'Report'):

        (1) The Report fully complies with the requirements of Section 13(a) or
    15(d) of the Securities Exchange Act of 1934, as amended; and

        (2) The information contained in the Report fairly presents, in all
    material respects, the financial condition and results of operations of the
    Registrant.

                                              /s/ ALBO J. ANTENUCCI, JR.
                                          .....................................
                                                  ALBO J. ANTENUCCI, JR.
                                          PRESIDENT AND CHIEF EXECUTIVE OFFICER
                                          OF AMERICAN PROPERTY INVESTORS, INC.,
                                                  THE GENERAL PARTNER OF
                                           AMERICAN REAL ESTATE PARTNERS, L.P.

Date: August 14, 2003
#### § 812.60 IRB composition, duties, and functions.

An IRB reviewing and approving investigations under this part shall comply with the requirements of part 56 in all respects, including its composition, duties, and functions.

[46 FR 8957, Jan. 27, 1981]
#### Stacia Silvester et al. *v.*Thomas Kerelejza

*John J. Langenbach,*for the appellant (defendant).

*George 8. Linardos,*for the appellees (plaintiffs).

Argued October 1

decided October 23, 1968

The motion by the defendant for judgment in the appeal from the Court of Common Pleas in Hartford County is denied.